In vivo models of cardiac diseases: application to drug development and screening

Bibliography

• Bhindi R, Witting PK, McMahon AC, Rat models of myocardial infarction. Thromb Haemost 2006;96:602-10
   PubMed Web of Science ®Google Scholar
• Recchia FA, Lionetti V. Animal models of dilated cardiomyopathy for translational research. Vet Res Commun 2007;31(Suppl 1):35-41
   PubMed Web of Science ®Google Scholar
• Killeen MJ, Thomas G, Sabir IN, Mouse models of human arrhythmia syndromes. Acta Physiol 2008;192:455-69
   PubMed Web of Science ®Google Scholar
• London B. Cardiac arrhythmias: from (transgenic) mice to men. J Cardiovasc Electrophysiol 2001;12(9):1089-91
   PubMed Web of Science ®Google Scholar
• Nilles KM, London B. Knockin animal models of inherited arrhythmogenic diseases: what have we learned from them? J Cardiovasc Electrophysiol 2007;18:1117-25
   PubMed Web of Science ®Google Scholar
• Abbott A. Laboratory animals: the renaissance rat. Nature 2004;428:464-6
   PubMed Web of Science ®Google Scholar
• Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 2007;56:1-10
   PubMedGoogle Scholar
• Chorro FJ, Such-Belenguer L, López-Merino V. Animal models of cardiovascular disease. Rev Esp Cardiol 2009;62:69-84
   PubMed Web of Science ®Google Scholar
• Muders F, Elsner D. Animal models of chronic heart failure. Pharmacol Res 2000;41(6):605-12
   PubMed Web of Science ®Google Scholar
• Hamlin RL. Animal models of ventricular arrhythmias. Pharmacol Ther 2007;113:276-95
   PubMed Web of Science ®Google Scholar
• Hearse DJ, Sutherland FJ. Experimental models for the study of cardiovascular function and disease. Pharmacol Res 2000;41:597-603
   PubMed Web of Science ®Google Scholar
• Wang QD, Bohlooly YM, Sjoquist PO. Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery. J Pharmacol Toxicol Methods 2004;50:163-74
   PubMedGoogle Scholar
• Ross J Jr. Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models. Circ J 2002;66:219-24
   PubMed Web of Science ®Google Scholar
• Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503-17
   PubMed Web of Science ®Google Scholar
• Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 2000;11:290-304
   PubMed Web of Science ®Google Scholar
• Holzgrefe HH, Everitt JM, Wright EM. Alpha-chloralose as a canine anesthetic. Lab Anim Sci 1987;37:587-95
   PubMedGoogle Scholar
• Puttick RM, Diedericks J, Sear JW, Effect of graded infusion rates of propofol on regional and global left ventricular function in the dog. Br J Anaesth 1992;69:375-81
   PubMed Web of Science ®Google Scholar
• Baumans V. Use of animals in experimental research: an ethical dilemma? Gene Ther 2004;11(Suppl 1):S64-6
   PubMed Web of Science ®Google Scholar
• Russell WMS, Burch RL. The principles of humane experimental technique. Methuen: London; 1959
   Google Scholar
• Montagnana M, Lippi G, Franchini M, Sudden cardiac death: prevalence, pathogenesis, and prevention. Ann Med 2008;40:360-75
   PubMed Web of Science ®Google Scholar
• Nattel S, Duker G, Carlsson L. Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 2008;98:328-39
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Arrhythmia models for drug research: classification of antiarrhythmic drugs. J Pharmacol Sci 2007;103:333-46
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984;69:790-800
   PubMed Web of Science ®Google Scholar
• Stroumpoulis K, Xanthos T, Rokas G, Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008;12:R40
   PubMed Web of Science ®Google Scholar
• Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415(6868):219-26
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008;10:647-65
   PubMed Web of Science ®Google Scholar
• Forleo GB, Tondo C. Atrial fibrillation: cure or treat? Ther Adv Cardiovasc Dis 2009;3:187-96
   PubMedGoogle Scholar
• Wijffels MC, Kirchhof CJ, Dorland R, Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68
   PubMed Web of Science ®Google Scholar
• Nattel S, Bourne G, Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol 1997;8(4):469-80
   PubMed Web of Science ®Google Scholar
• Nattel S, Shiroshita-Takeshita A, Brundel BJJM, Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 2005;48:9-28
   PubMed Web of Science ®Google Scholar
• Haugan K, Lam HR, Knudsen CB, Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: a new in vivo model. J Cardiovasc Pharmacol 2004;44(1):125-35
   PubMed Web of Science ®Google Scholar
• Blaauw Y, Gögelein H, Tieleman RG, “Early” class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-24
   PubMed Web of Science ®Google Scholar
• Li D, Bénardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000;102:104-12
   PubMed Web of Science ®Google Scholar
• Rivard L, Sinno H, Shiroshita-Takeshita A, The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. Cardiovasc Res 2007;74:104-13
   PubMed Web of Science ®Google Scholar
• Shinagawa K, Shi Y-F, Tardif J-C, Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672-8
   PubMed Web of Science ®Google Scholar
• Ortiz J, Niwano S, Abe H, Mapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. Circ Res 1994;74:882-94
   PubMed Web of Science ®Google Scholar
• Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008;154:1528-37
   PubMed Web of Science ®Google Scholar
• Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145-72
   PubMed Web of Science ®Google Scholar
• Oros A, Beekman JDM, Vos MA. The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther 2008;119:168-78
   PubMed Web of Science ®Google Scholar
• Carlsson L, Abrahamsson C, Andersson B, Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993;27:2186-93
   PubMed Web of Science ®Google Scholar
• Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 2006;259:70-80
   PubMed Web of Science ®Google Scholar
• Bretaud S, Lee S, Guo S. Sensitivity of zebrafish to environmental toxins implicated in parkinson's disease. Neurotoxicol Teratol 2004;26:857-64
   PubMed Web of Science ®Google Scholar
• Milan DJ, MacRae CA. Zebrafish genetic models for arrhythmia. Prog Biophys Mol Biol 2008;98:301-8
   PubMed Web of Science ®Google Scholar
• Chico TJA, Ingham PW, Crossman DC. Modeling cardiovascular disease in the zebrafish. Trends Cardiovasc Med 2008;18:150-5
   PubMed Web of Science ®Google Scholar
• Barros TP, Alderton WK, Reynolds HM, Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008;154:1400-13
   PubMed Web of Science ®Google Scholar
• Milan DJ, Peterson TA, Ruskin JN, Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003;107:1355-8
   PubMed Web of Science ®Google Scholar
• Mittelstadt SW, Hemenway CL, Craig MP, Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J Pharmacol Toxicol Methods 2008;57:100-5
   PubMedGoogle Scholar
• Peterson RT, Shaw SY, Peterson TA, Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctatioin. Nat Biotechnol 2004;22:595-9
   PubMed Web of Science ®Google Scholar
• Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18
   PubMed Web of Science ®Google Scholar
• Monnet E, Chachques JC. Animal models of heart failure: what is new? Ann Thorac Surg 2005;79:1445-53
   PubMed Web of Science ®Google Scholar
• Shirota K, Huang Y, Kawaguchi O, Functional recovery of the native heart after cardiomyoplasty in sheep with heart failure: passive and dynamic effects of volume loading. Ann Thorac Surg 2002;73:849-54
   PubMed Web of Science ®Google Scholar
• Toyoda Y, Okada M, Kashem MA, Effects of cardiomyoplasty on right ventricular filling during volume loading. Ann Thorac Surg 1998;65:1676-9
   PubMed Web of Science ®Google Scholar
• Cantor EJF, Babick AP, ZainishaVasanji, A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol 2005;38:777-86
   PubMed Web of Science ®Google Scholar
• Chen EP, Bittner HB, Tull F, An adult canine model of chronic pulmonary hypertension for cardiopulmonary transplantation. J Heart Lung Transplant 1997;16:538-47
   PubMed Web of Science ®Google Scholar
• Buermans HP, Redout EM, Schiel AE, Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. Physiol Genomics 2005;21:314-23
   PubMed Web of Science ®Google Scholar
• Li Z, Bing OH, Long X, Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997;272:H2313-9
   PubMed Web of Science ®Google Scholar
• Michael O'Donnell J, Narayan P, Bailey MQ, 31P-NMR analysis of congestive heart failure in the SHHF/Mcc-facp rat heart. J Mol Cell Cardiol 1998;30:235-41
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Pfeffer JM, Pfeffer MA. The transition to failure in the spontaneously hypertensive rat. Am J Hypertens 1997;10:120S-6S
   PubMed Web of Science ®Google Scholar
• Schlenker EH, Kost CK Jr, Likness MM. Effects of long-term captopril and L-arginine treatment on ventilation and blood pressure in obese male SHHF rats. J Appl Physiol 2004;97:1032-9
   PubMed Web of Science ®Google Scholar
• Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 1962;194:480-2
   PubMed Web of Science ®Google Scholar
• Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 1999;42:591-9
   PubMed Web of Science ®Google Scholar
• Elsner D, Riegger GA. Experimental heart failure produced by rapid ventricular pacing in the dog. J Card Fail 1995;1:229-47
   PubMedGoogle Scholar
• Takagaki M, McCarthy PM, Tabata T, Induction and maintenance of an experimental model of severe cardiomyopathy with a novel protocol of rapid ventricular pacing. J Thorac Cardiovasc Surg 2002;123:544-9
   PubMed Web of Science ®Google Scholar
• Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997;23:775-82
   PubMed Web of Science ®Google Scholar
• Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58
   PubMed Web of Science ®Google Scholar
• Tessier D, Lajos P, Braunberger E, Induction of chronic cardiac insufficiency by arteriovenous fistula and doxorubicin administration. J Card Surg 2003;18:307-11
   PubMed Web of Science ®Google Scholar
• Lucas CM, Cheriex EC, van der Veen FH, Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist devices. Cardiovasc Res 1992;26:804-9
   PubMed Web of Science ®Google Scholar
• Karalliedde L. Animal toxins. Br J Anaesth 1995;74:319-27
   PubMed Web of Science ®Google Scholar
• Rajnoch C, Chachques JC, Berrebi A, Cellular therapy reverses myocardial dysfunction. J Thorac Cardiovasc Surg 2001;121:871-8
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84
   PubMed Web of Science ®Google Scholar
• Hwang GS, Oh KS, Koo HN, Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. Eur J Pharmacol 2006;540:131-8
   PubMed Web of Science ®Google Scholar
• von Haehling S, Lainscak M, Springer J, Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-52
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Kojima M, Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001;104:1430-5
   PubMed Web of Science ®Google Scholar
• Moainie SL, Gorman JH III, Guy TS, An ovine model of postinfarction dilated cardiomyopathy. Ann Thorac Surg 2002;74:753-60
   PubMed Web of Science ®Google Scholar
• Bayat H, Swaney JS, Ander AN, Progressive heart failure after myocardial infarction in mice. Basic Res Cardiol 2002;97:206-13
   PubMed Web of Science ®Google Scholar
• Samsamshariat SA, Samsamshariat ZA, Movahed MR. A novel method for safe and accurate left anterior descending coronary artery ligation for research in rats. Cardiovasc Revasc Med 2005;6:121-3
   PubMedGoogle Scholar
• Braun A, Trigatti BL, Post MJ, Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002;90:270-6
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Buttgereit J, Pagel-Langenickel I, Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 2006;103:4735-40
   PubMed Web of Science ®Google Scholar
• de Boer RA, Pokharel S, Flesch M, Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-87
   PubMed Web of Science ®Google Scholar
• Olson TM, Michels VV, Thibodeau SN, Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-2
   PubMed Web of Science ®Google Scholar
• Arber S, Hunter JJ, Ross J Jr, MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997;88:393-403
   PubMed Web of Science ®Google Scholar
• Arber S, Halder G, Caroni P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 1994;79:221-31
   PubMed Web of Science ®Google Scholar
• Knoll R, Hoshijima M, Chien KR. Muscle LIM protein in heart failure. Exp Clin Cardiol 2002;7:104-5
   PubMedGoogle Scholar
• Hongo M, Ryoke T, Schoenfeld J, Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol 2000;95:431-41
   PubMed Web of Science ®Google Scholar
• Milner DJ, Weitzer G, Tran D, Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 1996;134:1255-70
   PubMed Web of Science ®Google Scholar
• Benjamin IJ, Schneider MD. Learning from failure: congestive heart failure in the postgenomic age. J Clin Invest 2005;115:495-9
   PubMed Web of Science ®Google Scholar
• Tidholm A, Jonsson L. Histologic characterization of canine dilated cardiomyopathy. Vet Pathol 2005;42:1-8
   PubMed Web of Science ®Google Scholar
• Ryoke T, Gu Y, Mao L, Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation 1999;100:1734-43
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Ross J Jr. Models of dilated cardiomyopathy in the mouse and the hamster. Curr Opin Cardiol 2000;15:197-201
   PubMed Web of Science ®Google Scholar
• Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20
   PubMed Web of Science ®Google Scholar
• Marian AJ. Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J 2009;36:194-204
   PubMed Web of Science ®Google Scholar
• Maass A, Leinwand LA. Animal models of hypertrophic cardiomyopathy. Curr Opin Cardiol 2000;15:189-96
   PubMed Web of Science ®Google Scholar
• Sanbe A, James J, Tuzcu V, Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation 2005;111:2330-38
   PubMed Web of Science ®Google Scholar
• Marian AJ, Wu Y, Lim D-S, A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 1999;104:1683-92
   PubMed Web of Science ®Google Scholar
• Patel R, Nagueh SF, Tsybouleva N, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24
   PubMed Web of Science ®Google Scholar
• Bauersachs J, Stork S, Kung M, HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007;37:852-9
   PubMed Web of Science ®Google Scholar
• Zhang SH, Reddick RL, Piedrahita JA, Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71
   PubMed Web of Science ®Google Scholar
• Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006;15:318-30
   PubMed Web of Science ®Google Scholar
• King VL, Trivedi DB, Gitlin JM, Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006;26:1137-43
   PubMed Web of Science ®Google Scholar
• Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler Thromb Vasc Biol 2005;25:267-69
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Brown MS, Goldstein JL, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-93
   PubMed Web of Science ®Google Scholar
• Zadelaar S, Kleemann R, Verschuren L, Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007;27:1706-21
   PubMed Web of Science ®Google Scholar
• Hasty AH, Shimano H, Osuga J, Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001;276:37402-8
   PubMed Web of Science ®Google Scholar
• Oltman CL, Richou LL, Davidson EP, Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2006;291:H1780-7
   PubMed Web of Science ®Google Scholar
• Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease–is it time to shift our goals? N Engl J Med 2005;352:1483-4
   PubMed Web of Science ®Google Scholar
• Dixon JL, Shen S, Vuchetich JP, Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J Lipid Res 2002;43:1618-29
   PubMed Web of Science ®Google Scholar
• Svendsen O. The minipig in toxicology. Exp Toxicol Pathol 2006;57:335-9
   PubMed Web of Science ®Google Scholar
• Drobnik J, Dabrowski R, Szczepanowska A, Response of aorta connective tissue matrix to injury caused by vassopressin-induced hypertension or hypercholesterolemia. J Physiol Pharmacol 2000;51:521-33
   PubMed Web of Science ®Google Scholar
• Richardson M, De Reske M, Delaney K, Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-1. Am J Pathol 1997;151:1009-17
   PubMed Web of Science ®Google Scholar
• Deten A, Volz HC, Briest W, Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002;55:329-40
   PubMed Web of Science ®Google Scholar
• Stanley WC. In vivo models of myocardial metabolism during ischemia: application to drug discovery and evaluation. J Pharmacol Toxicol Methods 2000;43:133-40
   PubMed Web of Science ®Google Scholar
• Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-46
   PubMed Web of Science ®Google Scholar
• Ytrehus K. The ischemic heart–experimental models. Pharmacol Res 2000;42:193-203
   PubMed Web of Science ®Google Scholar
• Naslund U, Haggmark S, Johansson G, A closed-chest myocardial occlusion-reperfusion model in the pig: techniques, morbidity and mortality. Eur Heart J 1992;13:1282-9
   PubMed Web of Science ®Google Scholar
• Chimenti S, Carlo E, Masson S, Myocardial infarction: animal models. Methods Mol Med 2004;98:217-26
   PubMedGoogle Scholar
• Straino S, Salloum FN, Baldi A, Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 2007;50:571-7
   PubMed Web of Science ®Google Scholar
• Vidavalur R, Swarnakar S, Thirunavukkarasu M, Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (i/r) injury: useful techniques for cardiovascular drug discovery. Curr Drug Discov Technol 2008;5:269-78
   PubMedGoogle Scholar
• Gross ER, Gross GJ. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 2007;12:367-88
   PubMed Web of Science ®Google Scholar
• Himori N, Matsuura A. A simple technique for occlusion and reperfusion of coronary artery in conscious rats. Am J Physiol 1989;256:H1719-25
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Sensebat O, Birnbaum Y, A novel minimal-invasive model of chronic myocardial infarction in swine. Coron Artery Dis 2004;15:7-12
   PubMed Web of Science ®Google Scholar
• Dewald O, Frangogiannis NG, Zoerlein MP, A murine model of ischemic cardiomyopathy induced by repetitive ischemia and reperfusion. Thorac Cardiovasc Surg 2004;52:305-11
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994;75:105-13
   PubMed Web of Science ®Google Scholar
• Zhou R, Xu Q, Zheng P, Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 2008;586:244-50
   PubMed Web of Science ®Google Scholar
• Touchard AG, Schwartz RS. Preclinical restenosis models: challenges and successes. Toxicol Pathol 2006;34:11-8
   PubMed Web of Science ®Google Scholar
• Bolli R, Becker L, Gross G, Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-34
   PubMed Web of Science ®Google Scholar
• Reynolds JC, Rittenberger JC, Menegazzi JJ. Drug administration in animal studies of cardiac arrest does not reflect human clinical experience. Resuscitation 2007;74:13-26
   PubMed Web of Science ®Google Scholar
• Epstein FH. MR in mouse models of cardiac disease. NMR Biomed 2007;20:238-55
   PubMed Web of Science ®Google Scholar